2023
DOI: 10.21873/invivo.13340
|View full text |Cite
|
Sign up to set email alerts
|

Smoking Status at Time of Diagnosis Affects the Efficacy of Anti-PD-1/L1 Therapy in Patients With Advanced NSCLC

KYU YEAN KIM,
JEONG UK LIM,
HYE SEON KANG
et al.

Abstract: Background/Aim: Programmed death ligand-1 (PD-L1) expression is known to be a predictive biomarker for response to immunotherapy in non-small cell lung cancer (NSCLC). However, PD-L1 is not always a reliable predictive biomarker. In the present study, we aimed to compare responses to immunotherapy according to smoking status in NSCLC patients receiving immunotherapy in second line or further line treatment. Patients and Methods: The lung cancer registry database of the Catholic Medical Center, Seoul, Republic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…Our team has previously proved prognostic nutritional index (PNI) as a reliable prognostic indicator for both ICI-treated NSCLC and small cell lung cancer (SCLC) patients ( 14 ). However, these prognostic indexes are mainly based on laboratory tests, ignoring individual status such as performance status (PS) and smoking status, which may be also crucial for ICI efficacy ( 15 , 16 ). Therefore, one or two parameters are far from sufficient to precisely stratify the outcome of ICI-treated NSCLC patients and novel predictive methods are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…Our team has previously proved prognostic nutritional index (PNI) as a reliable prognostic indicator for both ICI-treated NSCLC and small cell lung cancer (SCLC) patients ( 14 ). However, these prognostic indexes are mainly based on laboratory tests, ignoring individual status such as performance status (PS) and smoking status, which may be also crucial for ICI efficacy ( 15 , 16 ). Therefore, one or two parameters are far from sufficient to precisely stratify the outcome of ICI-treated NSCLC patients and novel predictive methods are urgently needed.…”
Section: Introductionmentioning
confidence: 99%